The Cyclin-Dependent Kinase (CDK) Inhibitor Flavopiridol Inhibits Glycogen Phosphorylase

This publication has 34 references indexed in Scilit:

• Identification of cytosolic aldehyde dehydrogenase 1 from non‐small cell lung carcinomas as a flavopiridol‐binding protein
  FEBS Letters, 1999
• Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
  Journal of Clinical Oncology, 1998
• Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells
  International Journal of Cancer, 1998
• The Novel Cyclin-Dependent Kinase Inhibitor Flavopiridol Downregulates Bcl-2 and Induces Growth Arrest and Apoptosis in Chronic B-Cell Leukemia Lines
  Blood, 1997
• From Bench Top to Bedside
  Science, 1997
• Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.
  Proceedings of the National Academy of Sciences, 1996
• Potent Inhibition of Cdc2 Kinase Activity by the Flavonoid L86-8275
  Biochemical and Biophysical Research Communications, 1994
• Growth Inhibition With Reversible Cell Cycle Arrest of Carcinoma Cells by Flavone L86-8275
  JNCI Journal of the National Cancer Institute, 1992
• Brain isozyme of glycogen phosphorylase: immunohistologicall localization within the central nervous system
  Brain Research, 1990
• McArdle's disease heterozygotes. Metabolic adaptation assessed using 31P-nuclear magnetic resonance.
  Journal of Clinical Investigation, 1986